JP7025416B2 - 好中球減少症を低減させるための組成物および方法 - Google Patents

好中球減少症を低減させるための組成物および方法 Download PDF

Info

Publication number
JP7025416B2
JP7025416B2 JP2019516091A JP2019516091A JP7025416B2 JP 7025416 B2 JP7025416 B2 JP 7025416B2 JP 2019516091 A JP2019516091 A JP 2019516091A JP 2019516091 A JP2019516091 A JP 2019516091A JP 7025416 B2 JP7025416 B2 JP 7025416B2
Authority
JP
Japan
Prior art keywords
chemotherapeutic
composition
administration
prinabrin
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019516091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521180A5 (enExample
JP2019521180A (ja
Inventor
ファン，ラン
ロイド，ジョージ，ケネス
モハンラル，ラモーン
Original Assignee
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド filed Critical ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Publication of JP2019521180A publication Critical patent/JP2019521180A/ja
Publication of JP2019521180A5 publication Critical patent/JP2019521180A5/ja
Priority to JP2022019473A priority Critical patent/JP7405881B2/ja
Application granted granted Critical
Publication of JP7025416B2 publication Critical patent/JP7025416B2/ja
Priority to JP2023211483A priority patent/JP2024028993A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019516091A 2016-06-06 2017-06-05 好中球減少症を低減させるための組成物および方法 Active JP7025416B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022019473A JP7405881B2 (ja) 2016-06-06 2022-02-10 好中球減少症を低減させるための組成物および方法
JP2023211483A JP2024028993A (ja) 2016-06-06 2023-12-14 好中球減少症を低減させるための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346426P 2016-06-06 2016-06-06
US62/346,426 2016-06-06
US201762454628P 2017-02-03 2017-02-03
US62/454,628 2017-02-03
PCT/US2017/035991 WO2017214052A1 (en) 2016-06-06 2017-06-05 Composition and method for reducing neutropenia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022019473A Division JP7405881B2 (ja) 2016-06-06 2022-02-10 好中球減少症を低減させるための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019521180A JP2019521180A (ja) 2019-07-25
JP2019521180A5 JP2019521180A5 (enExample) 2020-07-16
JP7025416B2 true JP7025416B2 (ja) 2022-02-24

Family

ID=60578094

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019516091A Active JP7025416B2 (ja) 2016-06-06 2017-06-05 好中球減少症を低減させるための組成物および方法
JP2022019473A Active JP7405881B2 (ja) 2016-06-06 2022-02-10 好中球減少症を低減させるための組成物および方法
JP2023211483A Withdrawn JP2024028993A (ja) 2016-06-06 2023-12-14 好中球減少症を低減させるための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022019473A Active JP7405881B2 (ja) 2016-06-06 2022-02-10 好中球減少症を低減させるための組成物および方法
JP2023211483A Withdrawn JP2024028993A (ja) 2016-06-06 2023-12-14 好中球減少症を低減させるための組成物および方法

Country Status (14)

Country Link
US (2) US11229642B2 (enExample)
EP (1) EP3463337A4 (enExample)
JP (3) JP7025416B2 (enExample)
KR (3) KR20190015361A (enExample)
CN (2) CN118304304A (enExample)
AU (1) AU2017278245B2 (enExample)
BR (1) BR112018074990A2 (enExample)
CL (1) CL2018003489A1 (enExample)
IL (1) IL263439B2 (enExample)
MX (1) MX389200B (enExample)
RU (1) RU2760348C2 (enExample)
SG (1) SG11201810872UA (enExample)
TW (1) TWI777957B (enExample)
WO (1) WO2017214052A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265091A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating a brain tumor
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
MX376122B (es) 2015-07-13 2025-03-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
BR112018074990A2 (pt) * 2016-06-06 2019-03-12 Beyondspring Pharmaceuticals, Inc. composição, usos e método para reduzir neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
EP3576733A4 (en) * 2017-02-01 2020-11-25 Beyondspring Pharmaceuticals, Inc. NEUTROPENIA REDUCTION METHOD
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN112105363A (zh) * 2018-02-01 2020-12-18 大连万春布林医药有限公司 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
US20240299377A1 (en) * 2019-10-15 2024-09-12 Beyondspring Pharmaceuticals, Inc. Methods and compositions for treating iron disorders
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
WO2023274316A1 (zh) * 2021-06-29 2023-01-05 深圳华泓海洋生物医药有限公司 氘代普那布林在制备治疗中性粒细胞减少症药物中的应用
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015051543A1 (en) 2013-10-11 2015-04-16 Dalian Wanchun Biotechnology Co., Ltd. Cancer treatment with combination of plinabulin and taxane

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU190774B (en) 1979-06-29 1986-11-28 The Wellcome Foundation Ltd,Gb Process for preparing ether derivatives with pharmacological activity
GB2090830B (en) 1980-12-18 1984-09-26 Wellcome Found Formyl ether derivatives
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
ES2096215T3 (es) 1992-10-01 1997-03-01 Wellcome Found Tucaresol como agente inmunopotenciador.
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
CA2149150C (en) 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
DE69842004D1 (de) 1997-11-21 2010-12-30 Purdue Neuroscience Co Substituierte 2-aminoacetamide und anwendung davon
HUP0101329A3 (en) 1998-01-29 2002-07-29 Aventis Pharmaceuticals Inc Co Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compounds and a cyclyzed compounds there from
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
CN1142909C (zh) 1998-03-26 2004-03-24 盐野义制药株式会社 具有抗病毒活性的吲哚衍生物
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CA2383424C (en) 1999-08-23 2011-02-15 Gordon Freeman Novel b7-4 molecules and uses therefor
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
JP4810043B2 (ja) 2000-01-18 2011-11-09 ネリアス・ファーマシュティカルズ・インコーポレーテッド 細胞分裂阻害剤及びその製造方法
WO2001070663A2 (en) 2000-03-17 2001-09-27 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
HUP0302358A3 (en) 2000-05-09 2007-09-28 Adpharma Piperazinedione compounds and use of them for producing pharmaceutical compositions
EP1345938A1 (en) 2000-12-28 2003-09-24 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
RU2321396C2 (ru) 2002-05-17 2008-04-10 Авентис Фарма С.А. Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
DK1529044T5 (da) 2002-08-02 2008-04-21 Nereus Pharmaceuticals Inc Dehydrophenylahistiner og analoger deraf og syntesen af dehydrophenylahistiner og analoger deraf
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
JP2007520565A (ja) 2004-02-04 2007-07-26 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成
HRP20160757T1 (hr) 2004-04-19 2016-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Postupak za proizvodnju polimorfnog oblika i od klopidogrel-vodik-sulfata
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1973569B1 (en) 2006-01-18 2013-05-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN101657213B (zh) 2007-02-15 2014-02-26 曼康公司 用于增强t细胞应答的方法
CN101678078B (zh) 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
CA2705417A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
ES2558568T3 (es) 2008-01-08 2016-02-05 Bristol-Myers Squibb Company Combinación de anticuerpo anti-CTLA4 con agentes moduladores de la tubulina para el tratamiento de enfermedades proliferativas
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
CA2749786A1 (en) 2009-01-16 2010-07-22 Jason Benjamin Bock New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
EP2403539A2 (en) 2009-03-02 2012-01-11 Massachusetts Institute of Technology Methods and systems for treatment and/or diagnosis
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
ES2543280T3 (es) 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
US20120114658A1 (en) 2009-09-15 2012-05-10 John Ryan Treatment of cancer
WO2011034954A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. Treatment of cancer
US20110274723A1 (en) 2009-10-23 2011-11-10 Mannkind Corporation Cancer immunotherapy and method of treatment
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
WO2011109625A1 (en) 2010-03-03 2011-09-09 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CA2799653A1 (en) 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
WO2012074904A2 (en) 2010-11-29 2012-06-07 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
AU2012344676A1 (en) 2011-11-28 2014-06-19 National Research Council Of Canada Paclitaxel response markers for cancer
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
WO2013124867A1 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
KR102165348B1 (ko) 2012-05-09 2020-10-14 캔텍스 파마슈티칼즈, 인크. 골수억제의 치료
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
WO2014036412A2 (en) 2012-08-30 2014-03-06 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
WO2014051543A1 (en) * 2012-09-25 2014-04-03 Hewlett-Packard Development Company, L.P. Print head die
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
PL2958943T3 (pl) 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
EP2988668B1 (en) 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
AU2014262469B2 (en) 2013-05-10 2019-11-14 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
HK1216231A1 (zh) 2013-06-03 2016-10-28 Novartis Ag Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物
JP6311097B2 (ja) 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
US20150273033A1 (en) 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
CN106232831B (zh) 2013-11-06 2021-02-26 美国卫生和人力服务部 通过表达谱分析对淋巴瘤类型进行亚型分类的方法
CN104796448B (zh) * 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
IL286282B2 (en) 2015-02-12 2023-10-01 Beyondspring Pharmaceuticals Inc Use of palinabolin in combination with immune checkpoint inhibitors
EP3265091A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating a brain tumor
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
CN106279039B (zh) 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
MX376122B (es) 2015-07-13 2025-03-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
BR112018074990A2 (pt) 2016-06-06 2019-03-12 Beyondspring Pharmaceuticals, Inc. composição, usos e método para reduzir neutropenia
JP6779517B2 (ja) 2016-09-02 2020-11-04 国立大学法人 鹿児島大学 抗癌剤の感受性及び癌の予後に対する診断マーカー
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
EP3576733A4 (en) 2017-02-01 2020-11-25 Beyondspring Pharmaceuticals, Inc. NEUTROPENIA REDUCTION METHOD
BR112019018880A2 (pt) 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals Inc composições de plinabulina e seu uso
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN112105363A (zh) 2018-02-01 2020-12-18 大连万春布林医药有限公司 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
CN110240592A (zh) 2018-03-08 2019-09-17 青岛海洋生物医药研究院股份有限公司 (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
US11590130B2 (en) 2018-04-05 2023-02-28 Noviga Research Ab Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer
US20210161888A1 (en) 2018-06-01 2021-06-03 Beyondspring Pharmaceuticals, Inc. Composition and method of treating cancer associated with egfr mutation
JP2021534183A (ja) 2018-08-16 2021-12-09 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 免疫応答を刺激するための方法及び組成物
JP2022513038A (ja) 2018-11-14 2022-02-07 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合薬を使用する癌の治療方法
US20240299377A1 (en) 2019-10-15 2024-09-12 Beyondspring Pharmaceuticals, Inc. Methods and compositions for treating iron disorders
CN112778155B (zh) 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
MX2022013808A (es) 2020-05-04 2023-02-09 Beyondspring Pharmaceuticals Inc Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad.
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN115703763A (zh) 2021-08-13 2023-02-17 大连万春布林医药有限公司 普那布林或其制剂中的杂质及其用途
WO2023060200A1 (en) 2021-10-07 2023-04-13 Beyondspring Pharmaceuticals, Inc. Methods for treating cancers and tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015051543A1 (en) 2013-10-11 2015-04-16 Dalian Wanchun Biotechnology Co., Ltd. Cancer treatment with combination of plinabulin and taxane

Also Published As

Publication number Publication date
RU2760348C2 (ru) 2021-11-24
JP2024028993A (ja) 2024-03-05
MX389200B (es) 2025-03-20
IL263439B1 (en) 2025-02-01
JP2022058964A (ja) 2022-04-12
JP2019521180A (ja) 2019-07-25
TWI777957B (zh) 2022-09-21
BR112018074990A2 (pt) 2019-03-12
CA3026455A1 (en) 2017-12-14
SG11201810872UA (en) 2019-01-30
US12433886B2 (en) 2025-10-07
AU2017278245A1 (en) 2018-12-20
US20220143013A1 (en) 2022-05-12
US11229642B2 (en) 2022-01-25
AU2017278245B2 (en) 2022-09-15
KR20190015361A (ko) 2019-02-13
KR20230018545A (ko) 2023-02-07
EP3463337A4 (en) 2020-02-12
NZ748877A (en) 2020-11-27
WO2017214052A1 (en) 2017-12-14
JP7405881B2 (ja) 2023-12-26
CN109475524A (zh) 2019-03-15
US20190175587A1 (en) 2019-06-13
MX2018015100A (es) 2019-09-04
KR20240091084A (ko) 2024-06-21
CN118304304A (zh) 2024-07-09
TW201801726A (zh) 2018-01-16
RU2018142394A (ru) 2020-07-10
IL263439B2 (en) 2025-06-01
IL263439A (en) 2019-01-31
RU2018142394A3 (enExample) 2020-08-18
EP3463337A1 (en) 2019-04-10
CL2018003489A1 (es) 2019-02-01

Similar Documents

Publication Publication Date Title
JP7025416B2 (ja) 好中球減少症を低減させるための組成物および方法
US12458638B2 (en) Method of stimulating neutrophil survival and reducing neutropenia
JP7350015B2 (ja) プリナブリンの投与による血小板減少症を軽減するための組成物および方法
JP2021512121A (ja) プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法
CA3026455C (en) Use of plinabulin for reducing neutropenia induced by chemotherapeutic agents
KR20260036390A (ko) 호중구감소증을 줄이는 조성물 및 방법
NZ748877B2 (en) Composition and method for reducing neutropenia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220210

R150 Certificate of patent or registration of utility model

Ref document number: 7025416

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250